Artiva Biotherapeutics
Allogeneic natural killer cell therapy platform for treating B cell malignancies and autoimmune diseases
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2019
- Latest Form D
- $120M, Apr 2021
- Total capital
- $163M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $163M
- 2 Form D · last Apr 2021
- 67 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 29 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$120M
- Private capital raisedForm D · SEC · 1st filing$43.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Bong J. KohDirectorNamed in SEC Form D filings
- Brian J. DanielsDirectorNamed in SEC Form D filings
- Esther J. van den BoomExecutive OfficerNamed in SEC Form D filings
- Fred AslanExecutive Officer, DirectorNamed in SEC Form D filings
- Jason J. LittenExecutive OfficerNamed in SEC Form D filings
- Jennifer J. BushExecutive OfficerNamed in SEC Form D filings
Show all 12 people
- Laura J. StoppelDirectorNamed in SEC Form D filings
- Peter J. FlynnExecutive OfficerNamed in SEC Form D filings
- Thomas J. FarrellExecutive Officer, DirectorNamed in SEC Form D filings
- Yong-Jun J. HuhDirectorNamed in SEC Form D filings
- Yu-Kyeong J. HwangDirectorNamed in SEC Form D filings
- Yvonne J. YamanakaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 29- PendingTreatment Of Autoimmune Disorders With Nk CellsUSPTOApplication 19484095
- PendingTreatment Of Autoimmune Disorders With Nk Cells And CD38 AntibodyUSPTOApplication PCTUS2025035294
- PendingAnti-bcma Antibody Or Antigen-binding Fragment Thereof, And Chimeric Antigen Receptor Comprising SameUSPTOApplication 19134363
Show all 29 patent records
- Treatment Of Autoimmune Disorders With Nk CellsApplication 19484095Pending
- Treatment Of Autoimmune Disorders With Nk Cells And CD38 AntibodyApplication PCTUS2025035294Pending
- Anti-bcma Antibody Or Antigen-binding Fragment Thereof, And Chimeric Antigen Receptor Comprising SameApplication 19134363Pending
- Treatment Of Autoimmune Disorders With Nk Cells And CD38 AntibodyApplication 63664290Pending
- Treatment Of B Cell Lymphomas With Nk Cells And A CD20 Targeted AntibodyApplication PCTUS2024033083Pending
- Treatment Of Cancer With Nk Cells And BendamustineApplication PCTUS2024030011Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication PCTUS2024029336Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication 63642218Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication 63556636Pending
- Anti-bcma Antibody Or Antigen-binding Fragment Thereof, And Chimeric Antigen Receptor Comprising SameApplication PCTUS2023082160Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication 63603850Pending
- Methods Of Administering Natural Killer Cells Comprising An Anti-human Epidermal Growth Factor Receptor 2 (HER2) Chimeric Antigen Receptor (car)Application PCTUS2023072337Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication 63513154Pending
- Chimeric Antigen Receptors And Use ThereofApplication 63508195Pending
- Treatment Of B Cell Lymphomas With Nk Cells And A CD20 Targeted AntibodyApplication 63507393Pending
- Treatment Of Cancer With Nk Cells And BendamustineApplication 63467860Pending
- Treatment Of Autoimmune Disorders With Nk CellsApplication 63466589Pending
- Anti-bcma Antibody Or Antigen-binding Fragment Thereof, And Chimeric Antigen Receptor Comprising SameApplication 63429910Pending
- Treatment Of Cancer With Nk Cells And Multispecific EngagersApplication PCTUS2022048887Pending
- Treatment Of Cancer With Nk Cells And A CD38 Targeted AntibodyApplication 63290351Pending
- Treatment Of Cancer With Nk Cells And A HER2 Targeted AntibodyApplication 63290359Pending
- Treatment Of Cancer With Nk Cells And An Egfr Targeted AntibodyApplication 63290361Pending
- Treatment Of Cancer With Nk Cells And A CD20 Targeted AntibodyApplication 63290349Pending
- Treatment Of Cancer With Nk Cells And A HER2 Targeted AntibodyApplication 63172414Pending
- Treatment Of Cancer With Nk Cells And A CD20 Targeted AntibodyApplication 63172401Pending
- Chimeric Antigen Receptors And Use ThereofApplication 19492465Pending
- Treatment Of Cancer With Nk Cells And An Egfr Targeted AntibodyApplication 63172423Pending
- Treatment Of Cancer With Nk Cells And A CD38 Targeted AntibodyApplication 63172424Pending
- Treatment Of Cancer With Nk Cells And A CD20 Targeted AntibodyApplication 63127098Pending
Related companies, and why
- Erasca, Inc.Similar federal contract value in Biotech · null in contracts
- Skye BioscienceSimilar federal contract value in Biotech · null in contracts
- LIGHT SWITCH BIO, LLCSimilar federal contract value in Biotech · null in contracts
- Verastem, Inc.Similar federal contract value in Biotech · null in contracts
- Solve TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Andira Medicine Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .